Fulgent Genetics (FLGT) Accounts Payables (2015 - 2026)

Fulgent Genetics has disclosed Accounts Payables across 12 years of filings, most recently posting $21.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $21.1 million, up 15.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.1 million (up 15.83% YoY), and the FY2025 annual result was $18.7 million, up 1.58% from the prior year.
• Accounts Payables came in at $21.1 million for Q1 2026 at Fulgent Genetics, up from $18.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $37.1 million in Q2 2022 to a low of $14.5 million in Q3 2022.
• The 5-year median for Accounts Payables is $19.6 million (2024), against an average of $20.3 million.
• Across the five-year window, Accounts Payables soared 151.71% in 2022 and sank 44.47% in 2023, its largest moves.
• Fulgent Genetics' Accounts Payables stood at $23.1 million in 2022, then plunged by 33.49% to $15.4 million in 2023, then advanced by 19.56% to $18.4 million in 2024, then rose by 1.58% to $18.7 million in 2025, then climbed by 13.25% to $21.1 million in 2026.
• The last three Accounts Payables figures came in at $21.1 million (Q1 2026), $18.7 million (Q4 2025), and $18.1 million (Q3 2025), per Business Quant data.